Adaptive study will look at impact of Sentrian’s Remote Patient Intelligence service on CareMore members with the goal of reducing avoidable hospitalization of COPD patients
ALISO VIEJO, CA. – May 4, 2015—Sentrian™, the Remote Patient Intelligence™ company aspiring to eliminate all preventable hospitalization,
has teamed with the Scripps Translational Science Institute (STSI) to study the effect of Sentrian technology on 1,000 patients with chronic obstructive pulmonary disease (COPD), a chronic condition that affects nearly 13 million Americans and is the nation’s third leading cause of death. The patients are all health plan members of CareMore Health System, a wholly owned subsidiary of Anthem.
The adaptive research study’s objective is to determine whether Sentrian’s Remote Patient Intelligence (RPI) platform can detect patient deterioration in advance of an acute event and with high accuracy, helping to reduce avoidable hospital admissions and readmissions for COPD patients while lowering their cost of care. Nationally, one in 11 patients with COPD are readmitted to a hospital within 30 days of discharge.
“This research collaboration with Sentrian and CareMore fits nicely with our mission at Scripps to study the latest advances in digital medicine technologies as part of our effort to replace traditional one-size-fits-all medicine with precision health care and to accelerate patient access to effective new approaches to treating illnesses,” said Dr. Steven Steinhubl, director of digital medicine at STSI.
Sentrian recently began providing an integrated remote patient monitoring and analytics service to 1,000 CareMore health plan members with COPD and other concomitant conditions. The patent-pending Sentrian RPI solution leverages remote biosensors and machine learning with the goal of remotely detecting deterioration in patients’ health with enough advance warning to intervene before the event becomes acute and requires hospitalization.
With Scripps’ participation, the project will evolve into a formal 12-month research study. The findings could significantly reform disease management not only for COPD, but for other chronic diseases —which account for 75 percent of U.S. health care costs.
“CareMore has long been a leader in using innovative approaches to better provide care for the chronically ill, including first generation remote patient monitoring,” said Dr. David Ramirez, vice president of clinical quality for CareMore. “Advanced analytics is the future of effective disease management in reducing hospital stays after an acute event, and providing for early prevention of traumatic episodes. This is exactly the kind of research study needed to get us to that future more quickly.”
Sentrian CEO Dean Sawyer confirmed the timely nature of the study.
“Millions of hospitalizations and tens of billions of dollars in cost could be avoided if we can detect health deterioration in patients with complex chronic disease days in advance. By working with scientific and health care leaders like Scripps and CareMore, I believe we can significantly reduce hospitalization and move toward the triple aim of health care – to simultaneously reduce cost, improve outcomes and improve patient satisfaction,” Sawyer stated.
Visit Sentrian at ATA15
Sentrian is demonstrating its RPI platform at the American Telemedicine Association’s annual conference in Los Angeles today in booth No. 1733.
Sentrian’s RPI platform includes the following services:
Identify: By analyzing client claims and/or clinical data, Sentrian’s risk-assessment engine identifies patients who are at the greatest risk of hospital admissions and who would benefit most from remote monitoring and analytics.
Monitor: Once the right patients are identified, Sentrian’s clinical team uses an advanced analytics engine to parse them by disease state, co-morbidities and other clinical indicators to determine the appropriate mix of remote biometric devices for their condition. Sentrian’s turnkey fulfillment solution manages the device delivery and activation process end-to-end for clients.
Analyze: Sentrian’s cloud-based analytics engine continuously runs the remotely acquired sensor data through a client-specific disease model, customized to consider a patient’s medical history, co-morbidities, exacerbations and health benchmarks. The disease model compares the sensor data against global rules of patient care, as well as against patient-specific trending to continuously determine a patient’s health risk. A proprietary closed-loop learning system allows the Sentrian RPI to integrate and learn from actual patient events and outcomes, and regularly optimize and fine-tune disease models toward improving the sensitivity and specificity of health risk estimation. This is achieved by continual data-driven discovery and recommendations to adjust the rules and parameters comprising the disease models.
Act: Care managers and clinicians are notified when a patient’s risk status has changed and may require their attention. These notifications are designed to provide care managers and clinicians with enough time to intervene with safer, lower-cost treatment options that keep patients healthy and happy at home.
CareMore Health System, a wholly owned subsidiary of Anthem, is the parent company of multiple health plans that operate under three federally approved Medicare Advantage contracts (“CareMore Health Plan subsidiaries”). The CareMore Health Plan subsidiaries serve a total of more than 80,000 Medicare members throughout Southern California, Northern California, Las Vegas, Phoenix and Tucson, Arizona. CareMore specializes in health care programs supporting Medicare beneficiaries from the healthy aging to the chronically ill and/or frail. Learn more at www.caremore.com.
About Scripps Translational Science Institute
Part of the San Diego, Calif.-based Scripps Health, the Scripps Translational Science Institute (STSI) is a unique community collaboration that embraces precision medicine by initiating research to move basic science from the lab to the patient bedside. STSI is supported by the National Institutes of Health flagship program, Clinical and Translational Science Award, awarded to The Scripps Research Institute in conjunction with its collaboration with STSI. The San Diego Supercomputer Center also is a collaborator in the STSI consortium. More information can be found at www.stsiweb.org.
Sentrian™, the first Remote Patient Intelligence ™ Company, aspires to eliminate all preventable hospitalization by leveraging the revolution in remote biosensors and machine learning to detect patient deterioration early, before it becomes acute. Sentrian’s value proposition to health care organizations is to provide a cloud-based remote patient monitoring and analytics platform intended to dramatically reduce preventable hospital admissions, increase the efficiency and effectiveness of care teams and improve quality metrics such as HEDIS and Star ratings. The Sentrian platform is designed to seamlessly integrate with existing healthcare information systems and clinical workflows, facilitating adoption. Sentrian is the sole winner of the American Telemedicine Association’s 2015 President’s Award for Innovation in Remote Health Care. Find us at www.sentrian.com, on Twitter and LinkedIn.
Sentrian™, the first Remote Patient Intelligence™ company, aspires to eliminate all preventable hospitalization by leveraging the revolution in remote biosensors and machine learning to detect patient deterioration early, before it becomes acute. Sentrian’s value proposition to healthcare organizations is to provide a cloud-based remote patient monitoring and analytics platform intended to dramatically reduce preventable hospital admissions, increase the efficiency and effectiveness of care teams and improve quality metrics such as HEDIS and Star ratings. The Sentrian platform is designed to seamlessly integrate with existing healthcare information systems and clinical workflows, facilitating adoption. Find us at www.sentrian.com, on Twitter and LinkedIn.